Recent Developments in Drug Targets and Combination Therapy for the Clinical Management of Hypertension.

Pradeep Kumar Niranjan, Shiv Bahadur
{"title":"Recent Developments in Drug Targets and Combination Therapy for the Clinical Management of Hypertension.","authors":"Pradeep Kumar Niranjan, Shiv Bahadur","doi":"10.2174/011871529X278907231120053559","DOIUrl":null,"url":null,"abstract":"<p><p>Raised blood pressure is the most common complication worldwide that may lead to atherosclerosis and ischemic heart disease. Unhealthy lifestyles, smoking, alcohol consumption, junk food, and genetic disorders are some of the causes of hypertension. To treat this condition, numerous antihypertensive medications are available, either alone or in combination, that work via various mechanisms of action. Combinational therapy provides a certain advantage over monotherapy in the sense that it acts in multi mechanism mode and minimal drug amount is required to elicit the desired therapeutic effect. Such therapy is given to patients with systolic blood pressure greater than 20 mmHg and/or diastolic blood pressure exceeding 10 mmHg beyond the normal range, as well as those suffering from severe cardiovascular disease. The selection of antihypertensive medications, such as calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and low-dose diuretics, hinges on their ability to manage blood pressure effectively and reduce cardiovascular disease risks. This review provides insights into the diverse monotherapy and combination therapy approaches used for elevated blood pressure management. In addition, it offers an analysis of combination therapy versus monotherapy and discusses the current status of these therapies, from researchbased findings to clinical trials.</p>","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular & hematological disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/011871529X278907231120053559","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Raised blood pressure is the most common complication worldwide that may lead to atherosclerosis and ischemic heart disease. Unhealthy lifestyles, smoking, alcohol consumption, junk food, and genetic disorders are some of the causes of hypertension. To treat this condition, numerous antihypertensive medications are available, either alone or in combination, that work via various mechanisms of action. Combinational therapy provides a certain advantage over monotherapy in the sense that it acts in multi mechanism mode and minimal drug amount is required to elicit the desired therapeutic effect. Such therapy is given to patients with systolic blood pressure greater than 20 mmHg and/or diastolic blood pressure exceeding 10 mmHg beyond the normal range, as well as those suffering from severe cardiovascular disease. The selection of antihypertensive medications, such as calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and low-dose diuretics, hinges on their ability to manage blood pressure effectively and reduce cardiovascular disease risks. This review provides insights into the diverse monotherapy and combination therapy approaches used for elevated blood pressure management. In addition, it offers an analysis of combination therapy versus monotherapy and discusses the current status of these therapies, from researchbased findings to clinical trials.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
高血压临床治疗药物靶点及联合治疗的最新进展。
血压升高是世界范围内最常见的并发症,可能导致动脉粥样硬化和缺血性心脏病。不健康的生活方式、吸烟、饮酒、垃圾食品和遗传疾病是高血压的一些原因。为了治疗这种情况,有许多抗高血压药物可用,无论是单独使用还是联合使用,它们通过不同的作用机制起作用。联合治疗与单一治疗相比具有一定的优势,因为它是多机制的,并且需要最少的药物量来达到预期的治疗效果。这种疗法适用于收缩压大于20mmhg和/或舒张压超过正常范围10mmhg的患者,以及患有严重心血管疾病的患者。降压药物的选择,如钙通道阻滞剂、血管紧张素转换酶(ACE)抑制剂、血管紧张素受体阻滞剂(ARBs)和低剂量利尿剂,取决于它们有效控制血压和降低心血管疾病风险的能力。这篇综述提供了不同的单一治疗和联合治疗方法用于高血压管理的见解。此外,它还提供了联合治疗与单一治疗的分析,并讨论了这些治疗的现状,从基于研究的发现到临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Acute Myeloid Leukemia Presenting as Extensive Arterial and Venous Thrombosis: A Case Report. Inter-atrial Septum Stenting in Congenital Heart Disease Patient: A Case Series in Indonesia. Exploring the Role of Secondary Metabolites from Plants and Microbes as Modulators of Macrophage Differentiation. Dengue Fever Related Reactive Thrombocytosis in Young Male: A Case Report and Review Literature. Toll-like Receptors: Therapeutic Potential in Life Threatening Diseases-Cardiac Disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1